<i>KRAS</i>,<i>NRAS</i>and<i>BRAF</i>mutations in Greek and Romanian patients with colorectal cancer: a cohort studyȘerban Negru, George Nasioulas, Eirini Papadopoulou et al.|BMJ Open|2014Cited by 43
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology GroupElena Fountzilas, G. Koumakis, Achilleas Nikolakopoulos et al.|ESMO Open|2020Cited by 38